At its Nov. 14 board meeting, CalPERS’ Pension and Health Benefits Committee directed its staff to move forward with a Request for Information (RFI) to implement a Full Reference Pricing Program, expanding from their currently proposed three drug class pilot (nasal corticosteroids, thyroid medications, and oral estrogens) to cover up to 70-80 drug classes.
CLSA’s state government relations team is pleased to share a brief update on some anticipated changes in the makeup of our California Legislature, state government and offer additional details on several key California races you may be interested in.
On the final day for signing or vetoing bills, California Gov. Jerry Brown signed into law SB 212 (Jackson), which establishes a comprehensive statewide take-back system for sharps and medications.
Two major bills of interest to CLSA have been presented to Governor Brown for his signing or veto: SB 1121 (Dodd), which was signed this week, and SB 212 (Jackson), on which we await action by the Governor. A third key bill of interest to CLSA, AB 2167 (Chau), died in the Senate during the final week of the legislative session.
On Aug. 29, California’s Office of Statewide Health Planning and Development (OSHPD) held a public hearing regarding proposed regulations to implement Senate Bill 17, which was signed into law last year.
California Life Sciences Association (CLSA) today urged Governor Jerry Brown to sign Senate Bill 1121, legislation that helps protect clinical trials conducted in California, which are the lifeblood of new and innovative medicines to treat patients in need. SB 1121 was approved by the California Legislature earlier this year and awaits action by Governor Brown, who has until Sept. 30 to sign or veto the legislation.
Assembly Bill 375, the California Consumer Privacy Act, will require companies that store large amounts of data, such as Google, Facebook, Twitter, and others, to disclose what kinds of data they collect, and give consumers more control over how that data is shared.
The California Life Sciences Association (CLSA) joined a coalition, which includes fellow life sciences trade associations, providers, insurers, and a number of other key stakeholders, to address the concerns related to HIPAA preemption and clinical trials data in the recently enacted AB 375, “The California Consumer Privacy Act of 2018” (“Privacy Act”), which will become effective January 1, 2020.
August has been a successful month for CLSA in educating the California state legislature on issues of critical importance to the life sciences industry in California.
California’s new Consumer Privacy Act (AB 375), the toughest data privacy law in the nation, will impose stringent new requirements on the state’s high-profile tech companies in 2020. Its impacts on the life sciences industry, though, remain unclear. CLSA’s State Government Relations team sat down with BioWorld to discuss what the measure means for innovative biomedical companies.